Description

Zenagamtide is a novel synthetic peptide designed as a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the amylin receptor. Belonging to the incretin mimetic class of research peptides, Zenagamtide represents an advanced tool for exploring the synergistic effects of two major hormonal pathways in glucose metabolism, appetite regulation, and energy homeostasis.

Unlike traditional GLP-1 receptor agonists that exclusively act on incretin signaling, Zenagamtide extends its research utility by engaging the amylin receptor system, which plays a pivotal role in postprandial satiety, gastric emptying, and weight regulation. This dual mechanism has attracted interest in studies of type 2 diabetes mellitus (T2DM), metabolic syndrome, and obesity, as well as in investigations of neuroendocrine signaling.

Zenagamtide’s peptide structure is engineered for stability, bioactivity, and receptor selectivity, allowing reliable reproducibility in laboratory models. Its amphipathic characteristics and receptor-binding profile make it a versatile candidate for comparative studies against other GLP-1 receptor agonists or amylin analogues.

Manufactured in a GMP-compliant facility, Zenagamtide is available in 98%+ purity, ensuring consistent quality for research use. It is suitable for applications in cell-based assays, preclinical pharmacology studies, and advanced metabolic research models. Researchers investigating synergistic incretin–amylin signaling or testing dual agonist strategies for metabolic disease intervention will find Zenagamtide to be a highly valuable peptide.

Zenagamtide is offered in wholesale and retail formats, making it a practical choice for academic laboratories, biotechnology firms, and pharmaceutical research institutions.

Important: Zenagamtide is supplied strictly for laboratory research use only and is not intended for human or veterinary applications.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Zenagamtide exerts its effects through dual activation of GLP-1 receptors and amylin receptors.

1. GLP-1 Receptor Agonism:

   • GLP-1 is an incretin hormone secreted from intestinal L-cells in response to food intake.

   • Zenagamtide binds to GLP-1 receptors on pancreatic ?-cells, enhancing glucose-stimulated insulin secretion.

   • It suppresses glucagon release from ?-cells, contributing to postprandial glucose regulation.

   • In gastrointestinal tissues, GLP-1 receptor stimulation slows gastric emptying, reducing glucose absorption rates.

2. Amylin Receptor Agonism:

   • Amylin, co-secreted with insulin, plays a vital role in satiety and postprandial glucose control.

   • Zenagamtide activates amylin receptors in the central nervous system, particularly the area postrema and hypothalamus, promoting satiety and reducing food intake.

   • In peripheral tissues, amylin receptor signaling slows gastric emptying and modulates nutrient absorption.

3. Dual Pathway Synergy:

   • By combining GLP-1 and amylin receptor activation, Zenagamtide mimics natural postprandial hormone interactions.

   • This synergy results in enhanced glucose regulation, appetite suppression, and metabolic balance in experimental models.

Research Applications

• Type 2 Diabetes Mellitus Research: Zenagamtide is used to explore novel dual agonist strategies for improving insulin sensitivity, glycemic control, and ?-cell preservation.

• Obesity and Appetite Regulation: Its amylin receptor agonism makes Zenagamtide suitable for studies investigating weight loss mechanisms and satiety signaling.

• Metabolic Syndrome Studies: Researchers employ Zenagamtide in models focusing on dyslipidemia, hypertension, and glucose dysregulation.

• Neuroendocrinology: Zenagamtide enables research into brain–gut signaling pathways that integrate appetite control with systemic metabolism.

• Comparative Pharmacology: The peptide is valuable in comparing mono-agonist vs. dual-agonist approaches, advancing the field of multi-target therapeutics.

By bridging incretin and amylin biology, Zenagamtide provides a unique research tool for developing next-generation metabolic therapies.

Side Effects (For Reference in Research Models)

In experimental settings, Zenagamtide has been observed to produce effects consistent with GLP-1 and amylin receptor agonists. While these observations are limited to laboratory models and not clinical use, researchers should note the following potential outcomes:

• Gastrointestinal Disturbances: Delayed gastric emptying may lead to nausea or reduced appetite in animal models.

• Altered Food Intake: Amylin receptor stimulation may suppress feeding behavior and body weight gain.

• Metabolic Shifts: Enhanced insulin secretion and glucose regulation may result in hypoglycemia under certain conditions.

• CNS Effects: As amylin receptors are located in the central nervous system, central satiety signaling may produce changes in feeding and behavior in research models.

• Comparative Effects: Compared to GLP-1 receptor agonists alone, dual agonism may amplify appetite suppression but also increase variability in gastrointestinal responses.

These effects are referenced strictly within the context of research models and are not indicative of clinical safety or efficacy.

Disclaimer

 is supplied strictly for laboratory research use only. It is not intended for human or veterinary use, drug, household, or diagnostic applications.

Keywords

Zenagamtide, GLP-1 agonist peptide, amylin receptor agonist, dual incretin amylin agonist, metabolic research peptide, obesity research, diabetes research peptide, GMP peptide supplier, laboratory use only peptide, wholesale peptide supplier